Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4672 - mCRC gene profiling using the Idylla platform

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Christopher Bricogne

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

C. Bricogne1, M. Rodriguez-Justo2, A. Agarwal3, S. Khan2, D. Patel2, N. Bhuva4, S. Brown5, R. Wikinson5, K. Shiu1

Author affiliations

  • 1 Oncology Department, University College London Hospital, Nw1 2bu - London/GB
  • 2 Pathology Department, University College London Hospital, Nw1 2bu - London/GB
  • 3 Pathology Department, Mount Vernon Hospital, HA6 2RN - London/GB
  • 4 Oncology Department, Mount Vernon Hospital, HA6 2RN - London/GB
  • 5 Oncology Department, Mount Vernon Hospital, London/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4672

Background

KRAS, NRAS and BRAF mutation testing for metastatic colorectal cancer (mCRC) is essential to guide treatment and prognostication. Multiple gene profiling assays are available, each with differing tumour sample size/quality requirements and turnaround time (TAT). Many UK hospitals send samples to off-site labs for profiling. A rapid TAT is desirable to plan appropriate chemotherapy +/- biologics from cycle one, as well as providing certainty and satisfaction for patients and clinicians.

Methods

This study was conducted at 2 UK tertiary cancer centres (University College London Hospital and Mount Vernon Hospital), comparing a pathway where gene profiling of mCRC was performed off-site using an NGS platform versus on-site testing using the Idylla platform (Biocartis, Mechelen, Belgium). Up to 50 patients were included in each group with 8 of the Idylla tests being used for samples that had failed with the NGS platform.

Results

Mutational profiling results for the whole cohort that were successfully tested (n = 84) showed 26% (22/84) were wildtype for KRAS/NRAS/BRAF, 62% (52/84) KRAS mutated, 2% (2/84) NRAS mutated, 10% (8/84) BRAF mutated. The median TAT in days (median, interquartile range (IQR)) of the on-site Idylla pathway was shorter than the off-site NGS pathway (4, 1 - 6 vs. 15, 13-17; p = <0.0001). In the off-site group median time from request to receipt of sample was 3 days (IQR 2 - 5) and median time from receipt to result was 10 days (IQR 9 - 13). Test failure rate was significantly higher with the NGS test (30%, 15/50) compared to the Idylla test (2%, 1/50) (p = 0.0001). 8 samples that had failed testing with the NGS platform, due to insufficient/low quality of sample, were all successfully tested with the Idylla platform.

Conclusions

For gene profiling of mCRC, on-site testing with the Idylla platform significantly shortened the TAT, lowered failure rate and was able to test more sub-optimal samples compared to off-site NGS testing. Updated results integrating these data with tumour location, MMR status and treatment outcomes will be presented at ESMO 2019.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Biocartis provided the Idylla test kits for this study without charge.

Disclosure

N. Bhuva: Honoraria (self), supported in attending international meetings: Amgen; Honoraria (self), supported in attending international meetings: Bristol-Myers Squibb. K. Shiu: Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Roche; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Merck Group; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Servier; Honoraria (self), Advisory / Consultancy, supported in attending lectures and conferences: Guardant Health. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.